Massard Julien, Ratziu Vlad, Thabut Dominique, Moussalli Joseph, Lebray Pascal, Benhamou Yves, Poynard Thierry
Service d'Hépato-Gastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
J Hepatol. 2006;44(1 Suppl):S19-24. doi: 10.1016/j.jhep.2005.11.009. Epub 2005 Nov 21.
Cirrhosis is the end-stage consequence of fibrosis progression in patients with chronic hepatitis C. The median time from infection to cirrhosis is 30 years, with a high inter-individual variability, which is now better understood. Several factors have been clearly shown to be associated with fibrosis progression rate: duration of infection, age, male gender, alcohol consumption, HIV co-infection and low CD4 count. Metabolic conditions such as steatosis, being overweight and diabetes are emerging as independent co-factors of fibrogenesis. The recent validation of non-invasive biomarkers should facilitate the study of fibrosis progression in large populations.
肝硬化是慢性丙型肝炎患者纤维化进展的终末期后果。从感染到肝硬化的中位时间为30年,个体间差异很大,目前对此有了更好的理解。已经明确显示,有几个因素与纤维化进展速度相关:感染持续时间、年龄、男性性别、饮酒、HIV合并感染和低CD4计数。诸如脂肪变性、超重和糖尿病等代谢状况正成为纤维化形成的独立协同因素。非侵入性生物标志物的近期验证应有助于在大量人群中研究纤维化进展。